Phase IIa Results Announced for Psoriasis Treatment

Phase IIa Results Announced for Psoriasis Treatment

DURECT Corporation announced top-line results from its phase IIa clinical trial of DUR-928 for mild to moderate plaque psoriasis. While the drug was well tolerated, it did not demonstrate a meaningful benefit over placebo in the trial, and DURECT will no longer be pursuing this indication, instead focusing on trials of DUR-928 for nonalcoloholic steatohepatitis (NASH). Will our extensive experience with clinical trials, Yourway knows the importance of agile decision making to determine which trials to terminate and which to pursue.

Back to Index

Upcoming Event

Clinical Trial Supply Europe

March 11-12, 2020
Madrid, Spain
Booth #54



Agility and Flexibility in a Company That Provides Both Courier and Clinical Packaging Services